Diabetes and Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer death in the United States. Risk factors for pancreatic cancer are smoking, family history, chronic pancreatitis, and diabetes. There is controversy with regards to the causal relationship between diabetes and pancreatic cancer because many patients with pancreatic cancer have new onset diabetes. Abstracts presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting highlighted and supported the positive association between pancreatic cancer and diabetes. Abstract #4102 reports a two-fold risk of pancreatic cancer in diabetic patients. Abstract #4063 also presented at the 2011 ASCO Meeting shows that metformin prolongs survival and decreases risk of death in patients with pancreatic malignancy and diabetes.
Image: Metformin disrupts G protein-coupled receptor and insulin signaling and pancreatic cancer growth.
Krejs GJ. Pancreatic cancer: epidemiology and risk factors. Dig Dis 2010; 28(2):355-8.
Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999 Jul; 189(1):1-7.
DiMagno EP. Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol 1999; 10(Suppl 4):S140-2.
Permert J, Larsson J, WestermarkGTet al. Islet amyloid polypeptide in patientswith pancreatic cancer and diabetes. N Engl J Med 1994; 330:313-8.
Schwarts SS, Zeidler A, Moossa AR, Kuku SF, Rubenstein AH. A prospective study of glucoseintolerance, insulin, C-peptide, and glucagon in patients with pancreaticcarcinoma. Am J Dig Dis 1978; 23:1107-14.
Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134:95-101.
Gullo, L. Diabetes and risk of pancreatic cancer. Ann Oncol 1999; 10(Suppl 4):S79-81.
Gullo L, Pezzilli R, Morselli-Labate AM. Italian Pancreatic Cancer Study Group: Diabetes and the risk of pancreatic cancer. N Engl J Med 1994; 331:81-4.
Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273(20):1605-9.
Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 2007; 96(3):507-509.
Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H, Li Z. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. European Journal of Cancer. March 2011; 1-7.
Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92(11):2076-2083.
Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293(2):194-202.
Bailey CJ, Turner RC. Drug therapy: metformin. N Engl J Med 1996; 334:574-9.
Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001; 120:1263-70.
Lee MS, Hsu CC, Wahlqvist M, Tsai HN, Chang, YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver, and pancreatic incidences in Taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011; 11:20:1-10.
Yacoub A, Siegel E, Makhoul E. Pancreatic cancer and diabetes mellitus: A retrospective cohort study. J Clin Oncol 2011; 29(Suppl.):4102.
Sadeghi N, Abbruzzese JL, Yeung SJ, Hassan M, Li D. Effect of metformin on survival of diabetic patients with pancreatic adenocarcinoma. J Clin Oncol 2011; 29(Suppl.):4063.
Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009; 69:6539-45.
Copyright (c) 2011 Christine Hsu, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.